on Bausch Health Companies Inc. (NASDAQ:BHC)
Salix Pharmaceuticals Highlights Challenges in Liver Disease Management
A recent Liver Health Trends Report by Bausch Health and Salix Pharmaceuticals emphasizes urgent improvements needed in liver disease management. The report shows chronic liver disease care often falls to non-specialists, requiring better education and resources for optimal patient outcomes.
The report finds approximately 4.5 million U.S. adults have chronic liver disease, frequently leading to cirrhosis. With chronic liver disease as a top-ten cause of death and rising mortality rates, timely diagnosis and prevention are crucial.
Healthcare providers suggest a shift to multidisciplinary care and the consistent use of non-invasive screening tools. The report calls for increased awareness, adoption of evidence-based guidelines, and advanced digital tools to manage liver disease more effectively.
Salix Pharmaceuticals aims to foster actionable change, leveraging resources to enhance liver disease management and address healthcare system burdens.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Bausch Health Companies Inc. news